What Investors Overlooked Before Neogen's 84% Run

Simply Wall St.11-09

If Neogen sat on your watchlist instead of in your portfolio, the move over the past year may sting. Holding Neogen over the past year would have returned 83.8%, including dividends. That sort of gain...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682829463?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868","is_english":true,"pubTime":"2026-11-09 05:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682829463","market":"hk","top_or_hot":-1,"title":"What Investors Overlooked Before Neogen's 84% Run","media":"Simply Wall St.","content":"<div>\n<p>If Neogen sat on your watchlist instead of in your portfolio, the move over the past year may sting. Holding Neogen over the past year would have returned 83.8%, including dividends. That sort of gain...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/what-investors-overlooked-before-neogens-84-run\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Investors Overlooked Before Neogen's 84% Run</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Investors Overlooked Before Neogen's 84% Run\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-09 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/what-investors-overlooked-before-neogens-84-run><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If Neogen sat on your watchlist instead of in your portfolio, the move over the past year may sting. Holding Neogen over the past year would have returned 83.8%, including dividends. That sort of gain...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/what-investors-overlooked-before-neogens-84-run\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/what-investors-overlooked-before-neogens-84-run","article_id":"2682829463","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/what-investors-overlooked-before-neogens-84-run","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682829463","pubTimestamp":1794172780,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","BK4211":"区域性银行","NEOG":"纽尔真检测","LU2211817866.USD":"Allianz Food Security AT Acc USD","BK4198":"医疗保健用品"},"translate_title":"Neogen 上涨 84% 之前投资者忽略了什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEOG":0.9,"ISBC":1.5},"content_text":"If Neogen sat on your watchlist instead of in your portfolio, the move over the past year may sting. Holding Neogen over the past year would have returned 83.8%, including dividends. That sort of gain invites a blunt question. What signals, already on record in late 2025, might have justified owning a loss-making diagnostics group on the assumption that rising profit margins from portfolio streamlining and new partnerships could eventually matter more than near term integration headaches? The move put Neogen in the middle of this trade. Scan 35 healthcare AI stocks for other companies exposed to it. AdvertisementThe Argument You Would Have Been Weighing Up On Neogen The shares cost US$5.98 at the start of the period, and anyone looking at Neogen then had to decide which of two very different stories sounded more reasonable. The bullish narrative saw upside to a Fair Value of US$6.5, a price implied by assumptions that tighter food safety rules and portfolio streamlining would allow higher future margins, even though analysts still expected revenue to fall 1.3% a year and did not project profits within three years. The bearish view pointed to a Fair Value of US$5, based on expectations that weak demand, a 1.5% annual revenue decline and ongoing 3M Food Safety integration problems could keep Neogen under earnings pressure despite the same long term margin target. NasdaqGS:NEOG 1-Year Stock Price Chart What The Neogen Evidence Actually Tested Neogen’s Q1 FY 2027 update showed revenue at US$222.8 million versus US$209.2 million a year earlier, which leaned toward the bullish case that tighter food safety rules and partnerships could support the top line. The same period reported a net loss of US$11.9 million compared with prior net income of US$36.3 million and a net margin that moved from 17.4% to a loss of 5.3%. That mix cut both ways for the original thesis on rising margins. The useful takeaway is simple: when a story hangs on better profitability, track net margin and absolute earnings alongside any upbeat revenue or guidance language. Then decide if the claimed margin journey is actually showing up in reported numbers at your next watchlist company. What Neogen’s Price Now Asks You To Believe Neogen shares trade at US$11.76, and the selected Narrative’s Fair Value sits above that level based on its own assumptions rather than any proven outcome. The argument leans on scale, consumables and efficiency gains as potential offsets to recall, regulatory and quality setbacks. On that view, today’s price does not fully credit the possibility that Neogen converts its installed base and analytics platform into higher recurring consumable use and stronger long term margins. \"If Neogen continues to convert its large installed base of more than 50,000 instruments and 70,000 customers into higher recurring consumable usage, including through Neogen Analytics where sites use more than 1.5x consumables, revenue and earnings could track closer to a compounding software and consumables model than the bearish case assumes.\" That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for One Step Beyond Neogen Neogen keeps you focused on lab results, contamination risks and regulatory pressure. One step away sits a different kind of healthcare engine. Where Neogen leans on diagnostics, this other business leans on care programs and digital plumbing. It tries to manage treatment plans, pharmacy spending and data handling in one loop. The goal is simple. Keep people healthier for longer, while squeezing waste from how care is delivered and paid for. To get there, it leans heavily on software, workflow tools and AI that targets back office drudgery. Claims, call centres and clinical paperwork all sit in scope. If that push really sticks, your watchlist might need to handle a very different healthcare story alongside Neogen. The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 22% above its price This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682829463","isCrawlerRequest":true}